Cleocin is a drug owned by Pfizer Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 20, 2020. Details of Cleocin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6495157 | Intravaginal clindamycin ovule composition |
Jul, 2020
(4 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Cleocin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cleocin's family patents as well as insights into ongoing legal events on those patents.
Cleocin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cleocin's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 20, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cleocin Generic API suppliers:
Clindamycin Phosphate is the generic name for the brand Cleocin. 13 different companies have already filed for the generic of Cleocin, with Zydus Pharms Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cleocin's generic
Alternative Brands for Cleocin
There are several other brand drugs using the same active ingredient (Clindamycin Phosphate) as Cleocin. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||||
|---|---|---|---|---|---|---|
| Almirall |
| |||||
| Bausch |
| |||||
| Norvium Bioscience |
| |||||
| Organon Llc |
| |||||
| Padagis Us |
| |||||
| Stiefel |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Clindamycin Phosphate, Cleocin's active ingredient. Check the complete list of approved generic manufacturers for Cleocin
About Cleocin
Cleocin is a drug owned by Pfizer Inc. Cleocin uses Clindamycin Phosphate as an active ingredient. Cleocin was launched by Pfizer in 1999.
Approval Date:
Cleocin was approved by FDA for market use on 13 August, 1999.
Active Ingredient:
Cleocin uses Clindamycin Phosphate as the active ingredient. Check out other Drugs and Companies using Clindamycin Phosphate ingredient
Dosage:
Cleocin is available in suppository form for vaginal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG | SUPPOSITORY | Prescription | VAGINAL |